LAVAL, QC, June 6, 2012 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") today advised that Roberto Bellini, President and Chief Executive Officer, will present at the 2012 Bloom Burton & Co. Healthcare Investor Conference. The presentation will take place at 4:00 pm Eastern Time on Thursday, June 21st, 2012. The conference is being held at the Toronto Board of Trade in Toronto, Ontario.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and European investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian public and private companies through presentations and break-out Q&A sessions.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company, in collaboration with its partner, Celtic Therapeutics Inc., is currently advancing its novel drug candidate KIACTA™, through a Phase III trial for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and eventually death. AA amyloidosis affects approximately 50,000 individuals in the United States, Europe and Japan.
For further information:
416-815-0700 ext. 248 | firstname.lastname@example.org